Boston Scientific Corporation (NYSE:BSX) EVP Timothy A. Pratt sold 11,061 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the sale, the executive vice president now owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 29.02 on Wednesday. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.50. The company’s 50-day moving average price is $28.06 and its 200 day moving average price is $26.92. The company has a market cap of $39.82 billion, a price-to-earnings ratio of 51.91 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm earned $0.27 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. On average, analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.watchlistnews.com/timothy-a-pratt-sells-11061-shares-of-boston-scientific-corporation-bsx-stock/1606722.html.

BSX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific Corporation in a research report on Tuesday. SunTrust Banks, Inc. restated a “buy” rating and issued a $34.00 target price on shares of Boston Scientific Corporation in a research note on Monday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, August 9th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $31.00 price target (up previously from $27.00) on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Finally, Cowen and Company reiterated a “buy” rating and set a $32.00 price target (up previously from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $30.12.

Several institutional investors have recently added to or reduced their stakes in BSX. Guardian Life Insurance Co. of America lifted its holdings in shares of Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares in the last quarter. Acrospire Investment Management LLC boosted its position in shares of Boston Scientific Corporation by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in shares of Boston Scientific Corporation by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after acquiring an additional 720 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new position in shares of Boston Scientific Corporation during the second quarter worth $191,000. Finally, Peddock Capital Advisors LLC purchased a new position in Boston Scientific Corporation during the second quarter valued at $201,000. Hedge funds and other institutional investors own 90.44% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.